W
ith advances in high-throughput screening capabilities, it is not difficult to identify compounds that target a particular protein or pathway. Rather, a greater challenge lies in identifying selective modulators and improving pharmaceutical, or ADMET (absorption, distribution, metabolism, excretion, and toxicity), properties of lead compounds (1) . In the traditional approach to pharmaceutical development, the initial efforts at lead optimization are focused on identifying structural analogues with the highest potency against a therapeutic target in in vitro assays. However, when the subsequent in vivo results clash with the predictions based on in vitro tests, it is difficult to determine whether such "failures" result from flawed biological underpinnings or compounds' intrinsic deficiencies, such as poor target selectivity or suboptimal in vivo bioavailability.
In principal, these pitfalls can be circumvented with the use of the in vivo zebrafish model early in the lead optimization phase. Rapid external development, transparency, and high fecundity make zebrafish ideal for large-scale in vivo characterization of bioactive small molecules (2−5) . Since embryonic cells are capable of integrating multiple signaling pathways to trigger precise developmental outputs, a small molecule that selectively targets a signaling pathway involved in embryonic patterning will phenocopy genetic mutations in that pathway, whereas nonspecific compounds will cause early embryonic lethality or nonspecific developmental delay. In addition, since drug exposure in embryos occurs by passive diffusion, the in vivo assessment takes into account compounds' intrinsic physiochemical prop-erties, such as the octanolϪwater partition coefficient (commonly referred to as log P), a major determinant of drug-likeness and bioactivity of a small molecule (6) . As a proof-of-principle, we identified dorsomorphin ( Figure 1 , panel a), the first selective small molecule inhibitor of BMP signaling, on the basis of its ability to phenocopy the dorsoventral (DV) pattern defects seen in the BMP pathway mutants ( Figure 1 , panel b) (7) .
Dorsomorphin and its analogue LDN-193189 have been used to direct differentiation of stem cells and to demonstrate the therapeutic potential of targeting BMP signals for anemia and hyperossification syndromes (7−9) . In particular, the discovery of dorsomorphin has immediate therapeutic implications for a debilitating heretofore incurable condition known as fibrodysplasia ossificans progressiva, which has recently been shown to be caused by activating mutations in ALK2 (ACVR1), a BMP type-I receptor (10−12) .
However, enthusiasm regarding their utility and therapeutic potential is tempered by the fact that dorsomorphin had significant "off-target" effects, including AMPK inhibition (13) . Since AMPK plays a central role in energy metabolism and is known to have beneficial cardiovascular and antitumor effects, inhibiting AMPK has potential to cause cardiotoxicity and promote tumorigenesis (14−16). Here we show that dorsomorphin also had significant inhibitory activity against the VEGF signaling and caused a significant defect in the intersomitic vessel (ISV) formation, an angiogenic process known to require signaling by the VEGF type-II receptor (also known as Vegfr2/Kdr/Flk1) (17−20) . However, because BMP signaling is also known to be involved in angiogenesis (21, 22) , it was possible that dorsomorphin treatment revealed a novel role of the BMP signal in ISV formation.
To distinguish between these possibilities and to generate additional potent and specific BMP and VEGF inhibitors, we undertook a large-scale in vivo SAR study of dorsomorphin analogues based on their effects on zebrafish embryos. We synthesized 63 distinct compounds using the parallel library synthesis approach and tested them in zebrafish embryos to identify highly selective and potent inhibitors of BMP as well as VEGF signaling. One of the analogues, DMH1, which exclusively targets BMP but not VEGF signaling, dorsalized the embryonic axis without disrupting ISV formation, demonstrating that BMP signaling is not required for zebrafish ISV formation.
RESULTS AND DISCUSSION
During the course of characterizing the effects of dorsomorphin ( Figure 1 , panel a) in zebrafish embryos, we found that it consistently caused significant defects in ISV formation (Figure 1, panel b) , an angiogenic process known to require signaling by the VEGF type-II receptors (Kdr/Flk1) (23) . To examine in detail dorsomorphin's effects on ISV formation, the Tg(fli:1a:EGFP)y1 transgenic embryos expressing GFP under the control of an endothelial-specific promoter (24) were treated with various concentrations (0.1Ϫ100 M) of dorsomorphin starting at 12 h post fertilization (hpf). Because this stage follows the establishment of the dorsoventral (DV) axis, this analysis focused only on dorsomorphin's effects on angiogenesis. After dorsomorphin treatment, ISV was visualized in live 48 hpf embryos. In this in vivo angiogenesis model, dorsomorphin completely inhibited ISV formation at 10 M (Figure 1 , panel b). At 5 M, roughly 50% of the ISV were severely shortened or eliminated (dorsomorphin's EC50, effective concentration affecting 50% of ISVs, was therefore 5 M; Table 1 ).
In cultured bovine aortic endothelial cells, dorsomorphin inhibited the VEGF-stimulated Flk1 phosphorylation in a dose-dependent manner (Figure 1 , panel c), demonstrating that dorsomorphin was a potent VEGF signal inhibitor. Nevertheless, since BMP signaling is also known to be involved in angiogenesis (21, 22) , it was formally possible that dorsomorphin's effects on the zebrafish vasculature revealed a novel role of the BMP signal in ISV formation. To test this, we sought to develop small molecules that specifically inhibited BMP but not VEGF signaling. Dorsomorphin (DM) and the selected analogues, along with the R1 and R2 structural modifications and the effects on zebrafish embryos with respect to the dorsoventral (DV) axis, the intersomitic vessel (ISV) disruption, and nonspecific toxicity. For dorsalization, the EC100 (effective concentration 100%) represents the concentration when 100% of the treated embryos are severely dorsalized. As a result of significant day-to-day variability in severity of dorsalization at "sub-threshold" concentrations, the EC50 for severe dorsalization could not be reliably determined. For ISV disruption, the EC50 represents the concentration when the formation of about 50% of the ISVs is inhibited. For nonspecific toxicity, the EC100 represents the concentration when 100% of the treated embryos exhibit either early lethality within hours of compound addition, variable embryonic defects, or developmental delay. For comparison, the effects of the known KDR inhibitor SU5416 are shown at the bottom. Results from at least 20 embryos per condition. Tables S1,  S2 ). Our effort was concentrated on varying two aspects of the dorsomorphin structure: the R 1 group (C-3 of the core structure) and the R 2 group (4-phenyl group on C-6 of the core structure) ( Figure 1 , panel d; Supplementary Tables S1, S2) (25) . The parallel library synthesis, as detailed in Supporting Information, led to the synthesis and isolation of 63 distinct compounds (Supplementary Tables S1, S2) .
Rather than the traditional approach of identifying structural analogues with the highest potency against BMP signaling in in vitro assays, the lead optimization effort was driven by the compounds' effects on live zebrafish embryos ( Figure 2 ). In vivo effective concentrations (ECs) and relative selectivities against BMP signaling were assessed after administering the compounds at 3 hpf. Because this stage represents a key temporal landmark in zebrafish development when multiple cell signaling pathways fashion the initial embryonic pattern, nonselective inhibitors will cause early lethality or nonspecific developmental defects, whereas the effects of selective BMP inhibitors will be limited to dorsalization of the embryonic axis. Of the initial set of 21 dorsomorphin analogues involving the modifications in the 6-position of the pyrazolo[1,5-a]pyrimidine backbone, 9 caused dorsalization without any associated early lethality, 7 caused early lethality, and 5 had no visible effect (Supplementary Table S1 ). Among the 9 dorsalizing compounds, those with the lower effective concentrations (ECs) were deemed to have greater anti-BMP potency in vivo. In this in vivo selectivity assessment, both dorsomorphin and the previously reported analogue LDN-193189 (9) caused substantial early lethality at 20 M, suggesting significant off-target effects (Table 1) .
Next, we examined the effects of the initial set of analogues and LDN-193189 on ISV formation by administering the compounds at 12 hpf and visualizing the ISV in live 48 hpf Tg(fli:1a:EGFP)y1 embryos. When the compounds were added at this stage, none caused gross morphologic defects or lethality within 24 h of administration. In this analysis of in vivo angiogenesis, LDN-193189 significantly inhibited ISV formation at 20 M (Table 1) . Of the initial 21 analogues, 7 had no effect on ISV formation (Table S1 ). Of these 7, two (92Y and 6L1) affected the DV axis, but only at high concentrations, indicating poor bioactivity (Table S1 ). The remaining five had no detectable in vivo activity, affecting neither ISV formation nor DV axis. Interestingly, included in this "inactive" group was 6LP, which was previously shown to have significant in vitro activity against KDR (IC50, concentration causing 50% inhibition, of 37nM) (26) (Supplementary Table 1 ). This discrepancy highlights the key fact that in vitro results do not necessarily predict in vivo bioactivity, presumably because they do not take into account a compound's solubility or bioavailability. The remaining 14 initial analogues affected both ISV formation and DV axis, although the individual impact on ISV formation and DV axis varied (Supplementary Table S1 ). In summary, the modifications at the 6-position had only a modest impact on conferring the selectivity for the DV axis. Thus, an additional round of derivatization was performed retaining several of the 6-position modifications (specifically analogues 6LE, 6K1, and 91E) that conferred enhanced bioactivity or relative selectivity and introducing modifications at the 3-position (Table 1; Supplementary Table S2 ). The modifications to the 3-position had a major impact on in vivo bioactivity and selectivity (Supplementary Table S2 ). Specifically, replacement of the 4-pyridyl group at the 3-position with a 4-quinoline group (9, 27) resulted in compounds with preferentially greater effect on DV axis over ISV formation (Table 1 ). Of particular interest were DMH1, DMH2, and DMH3, which did not have any detectible effect on ISV formation ( Figure 3 ; Table 1 ; Figure 4, (Table 1) . DMH2 was the most potent dorsalizing compound but less selective than DMH1 and DHM3 since it caused nonspecific developmental effects at higher concentrations ( Table 1) .
Replacement of the 4-pyridiyl group at the 3-position with a phenyl group resulted in compounds that preferentially effected ISV formation but not the DV axis (Table 1) . For example, DMH4, which had no discernible effect on the DV axis, caused significant defects in the ISV and the subintestinal vessel (SIV) ( Figure 3 ; Table 1 ; Figure 5 , panels a and b). Similar vascular defects have been noted in kdra mutants or in larvae treated with the Vegfr2 inhibitor SU5146 (19, 20) . DMH4's EC50 for ISV inhibition (effective concentration causing loss of 50% of ISVs) was 1 M, compared to 5 M for dorsomorphin (Table 1) .
Next, we examined the effects of DMH1, DMH2, and DMH3, the analogues exhibiting highest selectivity for DV patterning, in a number of in vitro assays. In a BMPresponsive luciferase reporter assay (28), the IC50s for DMH1, DMH2, and DMH3 were found to be approximately 100, 20, and 7 nM, respectively ( Figure 4 , panel b; Supplementary Figure S2 ). In addition, in vitro assays using the purified human BMP type-I receptor ALK2 (activin receptor like kinase-2) confirmed that DMH1, DMH2, and DMH3 were direct inhibitors of ALK2 (IC50s of 107.9, 42.8, and 26.7 nM, respectively) ( Table 2) .
Consistent with their minimal effect on ISV formation, in vitro assays using the purified human KDR demonstrated that DMH1, DMH2, and DMH3 had greatly diminished KDR activity in comparison to that of dorsomorphin and LDN-193189 (IC50 of Ͼ30, 2.4, and 2 M versus 25.1 and 214.7 nM, respectively; Table 2 ). Additional in vitro testing with the purified TGF␤ recep- tor ALK5, the AMPK, and the platelet-derived growth factor receptor-␤ (PDGFR␤) demonstrated that DMH1, DMH2, and DMH3 each had substantially higher IC50s for all of these targets than LDN-193189 did (Table 2) . Remarkably, DMH1 appeared to be very specific for ALK2 without any detectable inhibition of KDR, ALK5, AMPK, and PDGFR␤ (Table 2) . Importantly, the lack of ISV effects by DMH1, an exquisitely selective BMP inhibitor without any detectable KDR activity, demonstrates that the BMP signal, which is mediated by Smad1/5/8, is not required for zebrafish ISV formation.
On Western blots, DMH1, like dorsomorphin (7), selectively inhibited the BMP-induced Smad1/5/8 activation ( Figure 4, panel c) , but not the p38/MAP kinase signaling (Figure 4, panel c) or the Activin A-induced Smad2 activation (Figure 4, panel d) . Consistent with the in vitro kinase assay result, DHM1 had no effect on VEGFinduced Flk1 phosphorylation (Figure 4 , panel e). To determine whether DMH1 had subtype selectivity, we transfected the BMP signal reporter cells (28) with the constitutively active (ca) forms of the BMP type-I receptors ALK2, ALK3, and ALK6 (29) and examined DMH1's effect on BMP-responsive luciferase activity. In this assay, DMH1 effectively inhibited signaling by caALK2 and caALK3 (IC50 for both significantly less than 0.5 M) but had negligible effect on signaling by caALK6 (Supplementary Figure S3) . These results suggest that additional modifications may lead to further refinements in the subtype selectivity. From the clinical perspective, a more selective small molecule that targets just the ALK2, but not ALK3 or ALK6, would be desirable as a potential treatment for fibrodysplasia ossificans progressiva (10, 12) .
In the above in vivo SAR study, DMH4 had no discernible effect on DV ( Figure 5, panel b) , but caused significant defects in the ISV and SIV formation ( Figure 5 , panel a). Additionally, 1 M DMH4 effectively blocked angiogenesis in a Matrigel angiogenesis assay using human umbilical vein endothelial cells ( Figure 5, panel c) . These antiangiogenic effects of DMH4 were not mediated through BMP inhibition since, in in vitro BMP re- Shown are the IC50s (concentrations causing 50% inhibition) of DM and the analogues for the in vitro kinase assays using the following purified human enzymes: the BMP type-I receptor activin receptor-like kinase 2 (ALK2/BMPR-I), the TGF␤ type-I receptor activin receptor-like kinase 5 (ALK5/ TGF␤R-I), the VEGF type-2 receptor (VEGFR2/KDR), the AMP-activated protein kinase (AMPK), and the platelet-derived growth factor receptor-␤ (PDG-FR␤). In in vitro kinase assays, DM was relatively nonspecific, targeting ALK2, AMPK, and KDR with IC50s of Ͻ250 nM. LDN-193189 was slightly more selective but still had significant effects against ALK5 and KDR. By comparison, DMH1, DMH2, and DMH3 were much more selective ALK2 inhibitors. In particular, DMH1 had no detectible activity against any of the kinases tested besides ALK2. DMH4 was a selective KDR inhibitor with modest effect on ALK2 (IC50 3.6 M) and minimal effect on AMPK (IC50 8.0 M). Nonspecific kinase inhibitor staurosporine was used as a control. All of the reactions were carried out in the presence of 10 M ATP. no ϭ no inhibition; nt ϭ not tested. porter and purified ALK2 kinase assays, DMH4 did not inhibit BMP signaling at such low concentrations ( Figure 5 , panel d; Table 2 ). Rather, DMH4 effectively blocked VEGF-stimulated phosphorylation of both Flk1 and the downstream mediator Akt in a dose-dependent manner ( Figure 5 , panels e and f). Furthermore, in an in vitro assay using purified human Vegfr2 (KDR), DMH4 was found to be a direct inhibitor with an IC50 of 161 nM (Table 2) . Interestingly, in our in vivo angiogenesis analysis, the commonly utilized KDR inhibitor SU5146 (Semaxanib) (30) , which was originally developed as an antiangiogenesis therapy, was less potent than DMH4 and not selective (Table 1) . For several compounds, the IC50s based on the in vitro KDR kinase assays differed dramatically from the EC50s based on their effects on ISV formation (Tables 1,  2 ). For example, dorsomorphin, LDN-193189, and 6LP were potent KDR inhibitors in vitro (IC50s of 25.1, 214.7, and 37nM, respectively), yet all were relatively poor angiogenesis inhibitors in embryos (EC50s of 5, 20, and Ͼ50 M, respectively; Tables 1, 2 ). Such IC50ϪEC50 disparities may reflect suboptimal bioavailabilities of these compounds in later stage (ϳ24 hpf) embryos. In summary, the zebrafish proved to be an effective platform for the rapid identification of highly selective VEGF inhibitors with excellent in vivo potencies and favorable physiochemical properties.
Here, we utilized zebrafish to conduct the first fullscale in vivo SAR study in a vertebrate model to simultaneously identify selective small molecule inhibitors of BMP and VEGF pathways, both of which are recognized as important therapeutic targets. Our analyses indicate that modification of the 3-position of the pyrazolo[1,5-a]pyrimidine backbone of dorsomorphin plays a critical role in determining KDR versus BMP receptor selectivity. Using this approach, we identified a potent and selective KDR inhibitor (DMH4), as well as several highly selective BMP type-I receptor inhibitors, including DMH1, which does not target any of the related signaling pathways tested. Exquisitely selective BMP inhibitors, such as DMH1, that do not affect AMPK are preferred for further development as potential therapeutic leads since they should have reduced potential for cardiotoxicity and other undesired effects compared with the compounds that inhibit AMPK. Lastly, using DMH1, we demonstrated that BMP signaling is not required for angiogenesis in early zebrafish embryos.
The in vivo SAR's success in identifying potent and selective inhibitors of not only BMP but also VEGF signaling demonstrates that the zebrafish provides an effective multidimensional approach to simultaneously interrogate multiple pathways on a whole organism scale. Moreover, since the in vivo SAR study assesses the compounds' bioactivities in live embryos, this approach is inherently likely to identify compounds having favorable physiochemical properties and excellent "drug-likeness". Thus, this approach is useful for avoiding the pitfall of pursuing "dead end" leads, such as 6LP, which have excellent in vitro activity yet have poor in vivo bioactivity. The in vivo SAR study contrasts with the traditional in vitro assay-based SAR studies that focus on identifying analogues with the highest potency. Such a "linear approach", which does not take into account selectivity and physicochemical properties until later in drug development, can lead to compounds that ultimately fail in preclinical animal models despite having a compelling biological rationale. In conclusion, we demonstrate that the zebrafish is an attractive complementary platform for pharmaceutical development that incorporates the assessment of a lead compound's in vivo bioactivity and selectivity earlier in the development process.
METHODS
Zebrafish Experiments. The wild-type embryos were treated with various concentrations (0.1Ϫ100 M) of the compounds starting at 3 hpf to evaluate compounds' effects on the dorsoventral axis, and Tg(Fli:EGFP)y1 (18, 24) transgenic embryos were treated from 12 hpf to evaluate the effects on ISV formation. Twenty embryos were treated per well condition. Treated embryos were manually dechorionated and observed at 24, 48, and 72 hpf.
Cells and Cell Culture. C2C12, C2C12BRA, and bovine aortic endothelial cells (BAEC) were cultured in DMEM supplemented with 10% FBS (Gibco) and 1% penicillin/ streptomycin (Cellgro). The cells were then lysed, and cell extracts were then subjected to the firefly luciferase assay using Steady-Glo luciferase assay kit (Promega). The results were normalized to cell titers, as measured using Cell Titer-Glo luminescence assay (Promega). For subtype analysis, C2C12BRA cells were transiently transfected with plasmids (0.1 g) expressing constitutively active forms of the BMP type I receptors (caALK2, caALK3 or caALK6) using Lipofectamine kit (Invitrogen) in 96 well plates; 0.1 g of pRL-TK Renilla luciferase (Promega) was used to control for transfection efficiency. Relative activity was quantified by the ratio of firefly to Renilla luciferase activities using the dual luciferase assay kit (Promega).
Kinase Assay. All kinase assays were conducted by Reaction Biology Corp (Malvern, PA). In brief, compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 M, using nonspecific kinase inhibitor staurosporine as control. In vitro kinase reactions were carried out in the presence of 10 M ( 33 P)␥ATP. Five kinases tested were the human BMP type-I receptor activin receptor-like kinase 2 (ALK-2/ACVR1), the human TGF␤ type-I receptor activin receptor-like kinase 5 (Alk5/ TGF␤R1), the human VEGF type-II receptor (KDR/Flk-1/VEGFR2), the human AMP-activated protein kinase (AMPK/A1/B1/G1), and the human platelet-derived growth factor receptor-␤ (PDG-FR␤).
Chemical Synthesis. The synthetic chemistry effort was concentrated on varying two aspects of the 3,6-disubstituted pyrazolo [1,5-a] pyrimidine core of dorsomorphin (Supplementary Figure S3 ): the R 1 group (C-3 of the core structure) and the R 2 group (4-phenyl group on the C-6 of the core structure). Based on the known synthetic methods available, we varied the R 1 (phenyl, 2-, 3-, and 4-pyridyl, 3-quinoline, 4-quinoline, 2-thiophene, and 2-thiazole) and R 2 (alkyl ethers). Our library synthesis was focused on common intermediates 3 and 7, which were synthesized via different pathways depending on the 3-aryl substitution required (Supplementary Schemes S1, S2). For the phenyl and pyridyl derivatives, the synthesis started with the known 4-aryl-1H-pyrazol-5-amine 1 (31−33) , which was reacted with malondialdehyde 2 to afford the pyrazolo [1,5-a] pyrimidine core 3 (Supplementary Scheme S1). Next, the methoxy group was deprotected, and then the phenol was alkylated under basic conditions with a number of groups affording the final products 4 (Supplementary Tables S1, S2) (31) . For the other 3-heteroaryl-substituted pyrazolo[1,5-a]pyrimidine compounds 7, the commercially available 4-bromo-1H-pyrazol-5-amine 5 was reacted as above with malondialdehyde 2, which afforded the 3-bromo pyrazolo[1,5-a]pyrimidine core 6 (Supplementary Scheme S2). Next, 6 underwent transition-metalcatalyzed cross-coupling with either an appropriate boronic acid (34) or arylzinc bromide (35) to afford the desired 7. Compound 7 was then reacted as above to yield the final targets 4 (Supplementary Tables S1, S2 ). This reaction sequence was amenable to parallel library synthesis, and utilizing this approach led to the synthesis and isolation of 63 distinct compounds. Detailed synthesis schemes are discussed in Supporting Information.
